$2.09 Million in Sales Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter

Share on StockTwits

Equities analysts expect that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report sales of $2.09 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest sales estimate is $1.50 million and the highest is $3.31 million. Tetraphase Pharmaceuticals posted sales of $4.07 million during the same quarter last year, which suggests a negative year over year growth rate of 48.6%. The company is scheduled to report its next earnings report on Thursday, November 1st.

On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $16.68 million for the current year, with estimates ranging from $8.00 million to $21.28 million. For the next year, analysts anticipate that the business will report sales of $22.61 million per share, with estimates ranging from $12.00 million to $46.03 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.

A number of analysts have commented on the company. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 7th. ValuEngine upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. B. Riley upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 28th. HC Wainwright upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Finally, WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.41.

Large investors have recently added to or reduced their stakes in the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $104,000. Cubist Systematic Strategies LLC grew its position in shares of Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 24,837 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $179,000. Dynamic Technology Lab Private Ltd grew its position in shares of Tetraphase Pharmaceuticals by 322.1% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 58,079 shares in the last quarter. Finally, Alambic Investment Management L.P. purchased a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth about $356,000. Hedge funds and other institutional investors own 40.94% of the company’s stock.

TTPH traded down $0.07 during midday trading on Friday, reaching $3.07. The company had a trading volume of 439,103 shares, compared to its average volume of 1,261,593. Tetraphase Pharmaceuticals has a 1 year low of $2.05 and a 1 year high of $7.98.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: What is the NASDAQ?

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$2.09 Million in Sales Expected for Tetraphase Pharmaceuticals Inc  This Quarter
$2.09 Million in Sales Expected for Tetraphase Pharmaceuticals Inc This Quarter
FCoin Token  Achieves Market Capitalization of $0.00
FCoin Token Achieves Market Capitalization of $0.00
Incyte  Given “Buy” Rating at JPMorgan Chase & Co.
Incyte Given “Buy” Rating at JPMorgan Chase & Co.
SSE  Stock Rating Lowered by HSBC
SSE Stock Rating Lowered by HSBC
Leidos Holdings Inc  Shares Sold by Baird Financial Group Inc.
Leidos Holdings Inc Shares Sold by Baird Financial Group Inc.
Topps Tiles’  “Buy” Rating Reiterated at Peel Hunt
Topps Tiles’ “Buy” Rating Reiterated at Peel Hunt


Leave a Reply

© 2006-2018 Ticker Report. Google+.